0000000001304797

AUTHOR

H. Brunner

showing 44 related works from this author

Die Wirkung von Vasopressin auf die renale Wasser- und Salzausscheidung der Ratte bei Ver�nderungen der Salzkonzentration des Trinkwassers und nach N…

1956

An 13 Hypertonikern und 6 gesunden Personen wurden die Vergnderungen im funktionellen Zustand der BlutgefaBe der unteren Extremitaten nach Einspritzung yon isotonischer (1,8%) Magnesiumsulfatlosung in Dosen zu 5–25 cm3 und hypertonischer (10% und 25%) MagnesiumsulfatlSsung in Dosen yon 2–10 cm3 untersueht. Bei schnellem Einspritzen trat meistens Volumenverringerung der Extremitat ein, wahrend bei langsamem Einspritzen Vergroβerung oder Zweiphasenvergnderung erfolgte, die als Volumenverringerung und darauf folgende Volumenvergroβerung der Extremitat in Erscheinung trat. Die isotonische Losung verursacht entweder Volumenvergroβerung der Extremitat oder Zweiphasenveranderung — Verringerung und…

Pharmacologymedicine.medical_specialtyVasopressinKidneyChemistryPharmacology toxicologyGeneral MedicineResectionExcretionEndocrinologymedicine.anatomical_structureInternal medicineParenchymamedicineNaunyn-Schmiedebergs Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

�nderungen des Elektrolytgehalts von Erythrocyten und Plasma bei nephrektomierten Ratten

1957

After two-stage nephrectomy in rats the potassium concentration in the red blood corpuscles (RBC) decreases from 10.6 ± 0.3 to 5.5 ± 0.3 mEq per 100 ml of RBC within 48 h. The decrease is accompanied by a much smaller increase in the plasma potassium concentration; the hyperkaliemia in nephrectomized rats is less pronounced than in nephrectomized dogs or anuric humans. Na+ in RBC increases by about 44% after nephrectomy; while there is only a very slight decrease of Na+ in plasma. Plasma chlorides drop from 10.92 ± 0.08 mEq/100 ml of plasma to 6.00 ± 0.81 mEq % within 48 h after nephrectomy. RBC chlorides tend to increase again after an initial drop from 5.22 ± 0.07 to 3.82 ± 0.90 mEq% with…

medicine.medical_specialtyKidneyChemistrymedicine.medical_treatmentPotassiumchemistry.chemical_elementGeneral MedicineElectrolyteNephrectomyEndocrinologymedicine.anatomical_structureSerum potassiumInternal medicineDrug DiscoverymedicineMolecular MedicineWater-Electrolyte BalanceBlood corpusclesGenetics (clinical)Klinische Wochenschrift
researchProduct

Renale Wirkungen von Acetazolamid, Chlorothiazid und Chlormerodrin bei experimenteller Niereninsuffizienz

1959

Nach Darstellung der klinischen Befunde uber die Wirkung von Acetazolamid, Chlorothiazid und Chlormerodrin bei Niereninsuffizienz werden die Anderungen der Wirkungen der Diuretica durch Strahlermephritis, Pyelonephritis oder partielle Nephrektomie im Tierversuch besprochen.

Gynecologymedicine.medical_specialtybusiness.industrymedicineGeneral MedicinebusinessZeitschrift für Die Gesamte Experimentelle Medizin
researchProduct

Ausscheidung und Verteilung von Wasser und Mineralien nach oralen Gaben von physiologischer NaCl-L�sung bei der Ratte

1958

PharmacologyExcretionBiochemistryOral administrationChemistryEnvironmental chemistrySodiumPharmacology toxicologyWater metabolismchemistry.chemical_elementDistribution (pharmacology)General MedicineMetabolismNaunyn-Schmiedeberg's Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

Wirkungen von Acetazolamid, Chlorothiazid und Chlormerodrin auf die Clearance von Inulin, echtem endogenen Kreatinin, PAH und Harnstoff. Abgrenzung n…

1959

PharmacologyInulin ClearanceCreatininebusiness.industryGeneral MedicinePharmacologyNephrotoxicitychemistry.chemical_compoundchemistrymedicineUreaAminohippuric acidChlormerodrinAcetazolamidebusinessChlorothiazidemedicine.drugNaunyn-Schmiedeberg's Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

Die Beeinflussung der renalen Wasser- und Salzausscheidung normaler und hypophysektomierter Ratten durch Nebennierenrindenhormone

1956

PharmacologyGynecologymedicine.medical_specialtyChemistryPharmacology toxicologymedicineGeneral MedicineNaunyn-Schmiedebergs Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C

2003

Background: Peginterferon α-2b plus ribavirin therapy in previously untreated patients with chronic hepatitis C yields the highest sustained virological response rates of any treatment strategy but is expensive. Aims: To estimate the cost effectiveness of treatment with peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of patients with chronic hepatitis C. Methods: Individual patient level data from a randomised clinical trial with peginterferon plus ribavirin were applied to a previously published and validated Markov model to project lifelong clinical outcomes. Quality of life and economic estimates were based on German patient data. We u…

medicine.medical_specialtyCost effectivenessbusiness.industryRibavirinGastroenterologyvirus diseasesAlpha interferonHepatitis CWirtschaftswissenschaftenmedicine.diseaseGastroenterologySurgeryQuality-adjusted life yearClinical trialchemistry.chemical_compoundchemistryInternal medicinemedicinebusinessViral loadInterferon alfamedicine.drug
researchProduct

Der Tag-Nacht-Rhythmus der Diurese, Elektrolytausscheidung und Clearance des echten endogenen Kreatinins bei der Ratte

1956

PharmacologyCreatininechemistry.chemical_compoundmedicine.medical_specialtyRhythmEndocrinologychemistryInternal medicinePharmacology toxicologymedicineDiuresisGeneral MedicineElectrolyte excretionNaunyn-Schmiedebergs Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

Der Einfluss von Oxytocin auf Diurese und Salzausscheidung bei Ratte und Mensch

1956

chemistry.chemical_classificationmedicine.medical_specialtyChemistrySalt (chemistry)DiuresisGeneral MedicineMolecular medicineExcretionEndocrinologyOxytocinInternal medicineDrug DiscoverymedicineMolecular MedicineGenetics (clinical)medicine.drugKlinische Wochenschrift
researchProduct

Der Einflu� von Oxytocin auf die renale Wasser- und Salzausscheidung der Ratte

1956

Es wird zunaichst uber die Steigerung des Glutaminsaure/Glutamingehaltes einzelner Organe nach Futterung hoher Dosen Glutaminsaure berichtet, weiterhin die Frage zu klaren versucht, ob die nach Futterung hoher Glutaminsauredosen auftretende Bradykardie zentralen Ursprungs ist. Schlieβlich wird a u f die Beeinfluβung des Glutaminsaiurestoffwechsels durch Folsaure eingegangen, d i e als Storung der Acetyleholinbildung gedeutet wird.

PharmacologyExcretionmedicine.medical_specialtyEndocrinologyOxytocinChemistryInternal medicinePharmacology toxicologymedicineGeneral Medicinemedicine.drugNaunyn-Schmiedebergs Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

Die Wasserdiurese und ihre Begrenzung nach ein- oder mehrmaliger oraler Gabe von Wasser bei der Ratte

1958

PharmacologyGynecologymedicine.medical_specialtyChemistryPharmacology toxicologymedicineWater metabolismGeneral MedicineNaunyn-Schmiedeberg's Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

Renale Wasser- und Elektrolytausscheidung durstender Ratten innerhalb von 32 Stunden nach einmaliger intraven�ser Gabe von Chlormerodrin oder Mersalyl

1959

At the beginning of a period of hunger and thirst, rats received 3 or 4,5 to 5 mg.Hg/kg. as chlormerodrine or mersalyl. The optimal dose of 3mg Hg/kg.as chlormerodrine or 4,5mg. Hg/kg. as mersalyl was effective for more than 32 hours after a single injection.

PharmacologyIntravenous dosebusiness.industryGeneral MedicineSingle injectionPharmacologyElectrolyte excretionMersalylThirstchemistry.chemical_compoundchemistryChlormerodrineRenal physiologyMedicineChlormerodrinmedicine.symptombusinessNaunyn-Schmiedeberg's Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

Ver�nderungen von Funktion und Struktur der Nieren nach partieller Nephrektomie bei Ratten

1960

PharmacologyGynecologymedicine.medical_specialtybusiness.industryPharmacology toxicologyMedicineGeneral MedicinebusinessNaunyn-Schmiedeberg's Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

Änderungen des Elektrolytgehaltes von Erythrozyten und Plasma bei nephrektomierten Ratten

1957

After two-stage nephrectomy in rats the potassium concentration in the red blood corpuscles (RBC) decreases from 10.6 ± 0.3 to 5.5 ± 0.3 mEq per 100 ml of RBC within 48 h. The decrease is accompanied by a much smaller increase in the plasma potassium concentration; the hyperkaliemia in nephrectomized rats is less pronounced than in nephrectomized dogs or anuric humans. Na+ in RBC increases by about 44% after nephrectomy; while there is only a very slight decrease of Na+ in plasma. Plasma chlorides drop from 10.92 ± 0.08 mEq/100 ml of plasma to 6.00 ± 0.81 mEq % within 48 h after nephrectomy. RBC chlorides tend to increase again after an initial drop from 5.22 ± 0.07 to 3.82 ± 0.90 mEq% with…

Pharmacologymedicine.medical_specialtyChemistrymedicine.medical_treatmentPotassiumchemistry.chemical_elementCell BiologyNephrectomyCellular and Molecular NeuroscienceEndocrinologySerum potassiumBiochemistryInternal medicinemedicineMolecular MedicineBlood corpusclesMolecular BiologyExperientia
researchProduct

Ver�nderungen der Form der Tubuli und des Wassergehalts der Nieren bei der Mannit- und Sulfatdiurese der Ratte

1958

PharmacologyGynecologymedicine.medical_specialtybusiness.industryPharmacology toxicologymedicineDiuresisGeneral MedicinebusinessNaunyn-Schmiedeberg's Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

Die Verteilung von Wasser, Natrium und Kalium im Organismus der Ratte nach einer gro�en oralen Wassergabe

1958

PharmacologyChemistryPharmacology toxicologyWater metabolismGeneral MedicineMolecular biologyNaunyn-Schmiedeberg's Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

Histologische und histoautoradiographische Untersuchungen zur Wanddicke und zum Zellumsatz am interponierten Hundedünndarm nach totaler Gastrektomie

1979

Total gastrectomy was performed on purebred beagle dogs and a 30--40 cm jejunal segment was grafted isoperistaltically between oesophagus and duodenum. Histological and histoautoradiographical examinations were carried out and the wall-thickness and the cell-transformation rate in the interponate determined. Despite the isoperistaltic substitute-stomach a muscular wall-hypertrophy of 140% of the interponated jejunum was found. The reason for this hypertrophy is thought to be the result of adhesions and the functional mechanical demands. Histoautoradiographical examinations confirmed that the regeneration time in the substitute-stomach decreased by 70% compared with the normal jejunum. The d…

medicine.medical_specialtybusiness.industryRegeneration (biology)medicine.medical_treatmentdigestive oral and skin physiologyGeneral Medicinedigestive systemBeagleGastroenterologyMuscle hypertrophyJejunumTransplantationmedicine.anatomical_structureInternal medicineDuodenumMedicineGastrectomybusinessResearch in Experimental Medicine
researchProduct

Ver�nderungen der Wasser- und Salzausscheidung sowie der Nierenstruktur w�hrend des 2.?10. Tages nach einmaliger intraven�ser Zufuhr von Chlormerodrin

1959

Pharmacologychemistry.chemical_classificationIntravenous dosebusiness.industryPharmacology toxicologyKidney pharmacologySalt (chemistry)Kidney structureGeneral MedicinePharmacologyExcretionchemistryWater metabolismMedicinebusinessNaunyn-Schmiedeberg's Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

Die Wirkungsdauer des Quecksilberdiureticum Chlormerodrin an der Rattenniere

1959

Bei Ratten, die eine einmalige intravenose Injektion von Chlormerodrin (3,0 oder 5,0 mg Hg/kg) erhalten hatten, wurde die nach Ausscheidung von Wasser-, Natrium, Kalium und Chlorid wahrend 8 Std-Perioden fur 10 Tage nach der Injektion untersucht. Wahrend der Harnsammelperioden hungerten und dursteten die Tiere. Chlormerodrin steigerte in den ersten 2 Tagen nach der Injektion die Ausscheidung von Wasser, Natrium und Kalium aber nicht die von Chlorid. Nach einem Intervall mit fast normaler Harnausscheidung, das je nach Dosis 1–3 Tage dauerte, kam es am 4.–6. Tag nach der Injektion zu einer langdauernden Erhohung der Wasser-, Natrium- und Chloridausscheidung, die diesmal aber nicht mit einer S…

Gynecologymedicine.medical_specialtyChemistryDrug DiscoverymedicineMolecular MedicineGeneral MedicineGenetics (clinical)Klinische Wochenschrift
researchProduct

Der Einflu� einer ven�sen Stauung im Kopfbereich auf die Wasser- und Elektrolytausscheidung von Ratten

1960

1. Salt and water retention can be produced in rats by compression in the neck region or by ligature of the jugular veins.

PharmacologyChemistrymedicine.medical_treatmentfungiPharmacology toxicologyfood and beveragesGeneral MedicineAnatomyElectrolyte excretionmedicine.diseaseCompression (physics)Water retentionVenous stasissurgical procedures operativecardiovascular systemmedicineHead (vessel)medicine.symptomLigatureNaunyn-Schmiedeberg's Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

Splenic respiratory gas exchange and glucose uptake in patients with splenomegaly in hypersplenism and Hodgkin's disease.

1977

Blood samples are taken from the splenic artery, vein and pulp of patients suffering from Hodgkin's disease (n=10) or hypersplenism (n=7) and undergoing splenectomy. In these samples, the relevant parameters of the respiratory gas exchange as well as glucose and lactate concentrations are determined. In hypersplenism (mean splenic wet weight: 543 g) the mean oxygen consumption of the splenic tissue amounts to 0.9 ml O2/100 g/min taking into account a mean splenic blood flow of 80 ml/100 g/min. The glucose uptake and the lactate release are 9 mg/100 g/min and 5.5 mg/100 g/min, respectively. These values are in close agreement with the results obtained in the normal and undisturbed spleen in …

medicine.medical_specialtyErythrocytesGlucose uptakeRespiratory gas exchangechemistry.chemical_elementSpleenSplenic arteryOxygenHypersplenismVeinsOxygen Consumptionmedicine.arteryInternal medicineDrug DiscoverymedicineHumansIn patientGenetics (clinical)business.industryGeneral MedicineVenous bloodHydrogen-Ion ConcentrationHodgkin DiseaseSurgerymedicine.anatomical_structureEndocrinologyGlucosechemistrySplenic TissueSplenomegalyLactatesMolecular MedicinebusinessSplenic ArterySpleenKlinische Wochenschrift
researchProduct

Der Einflu� von nat�rlichem und synthetischem Oxytocin auf endogene Kreatinin-Clearance, Salzausscheidung und S�ureausscheidungsf�higkeit der Ratte u…

1957

Pharmacologychemistry.chemical_classificationmedicine.medical_specialtyChemistryPharmacology toxicologyRenal functionSalt (chemistry)DiuresisEndogenyGeneral MedicineExcretionEndocrinologyOxytocinInternal medicinemedicinemedicine.drugNaunyn-Schmiedebergs Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

Die Beeinflussung eines experimentellen Stauungs�dems der Ratte durch Chlorothiazid, Hydrocortison, Dexamethason, DOCA und Vasopressin

1960

Experiments on rats were made to determine which drugs were capable of preventing the formation of an experimental obstruction edema.

PharmacologyVasopressinmedicine.medical_specialtybusiness.industryeducationPharmacology toxicologyGeneral Medicineurologic and male genital diseasesEndocrinologyEdemaInternal medicinemedicinePrednisolonemedicine.symptombusinessDexamethasoneChlorothiazideHydrocortisonemedicine.drugNaunyn-Schmiedeberg's Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

CCDC 182718: Experimental Crystal Structure Determination

2003

Related Article: M.Brandl, H.Brunner, H.Cattey, Y.Mugnier, J.Wachter, M.Zabel|2002|J.Organomet.Chem.|659|22|doi:10.1016/S0022-328X(02)01663-7

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters(mu~3~-Tellurido)-bis(mu~2~-hydrido)-(mu~2~-bis(diphenylphosphino)methane)-heptacarbonyl-tri-ruthenium dichloromethane solvateExperimental 3D Coordinates
researchProduct

CCDC 171078: Experimental Crystal Structure Determination

2003

Related Article: M.Brandl, H.Brunner, H.Cattey, Y.Mugnier, J.Wachter, M.Zabel|2002|J.Organomet.Chem.|659|22|doi:10.1016/S0022-328X(02)01663-7

Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersDicarbonyl-bis(eta^5^-pentamethyl-cyclopentadienyl)-niobium (mu~3~-hydrido)-tris(mu~3~-tellurido)-pentadecacarbonyl-hexa-rutheniumExperimental 3D Coordinates
researchProduct

CCDC 127036: Experimental Crystal Structure Determination

2000

Related Article: H.Brunner, D.Lucas, T.Monzon, Y.Mugnier, B.Nuber, B.Stubenhofer, A.C.Stuckl, J.Wachter, R.Wanninger, M.Zabel|2000|Chem.-Eur.J.|6|493|doi:10.1002/(SICI)1521-3765(20000204)6:3<493::AID-CHEM493>3.0.CO;2-E

Space GroupCrystallographyCrystal SystemCrystal StructureDicarbonyl-bis(eta^5^-pentamethylcyclopentadienyl)-niobium(iii) (mu~10~-cobalt)-bis(mu~6~-tellurido)-pentakis(mu~4~-tellurido)-decakis(carbonyl-cobalt)Cell ParametersExperimental 3D Coordinates
researchProduct

CCDC 143351: Experimental Crystal Structure Determination

2001

Related Article: O.Blacque, H.Brunner, M.M.Kubicki, F.Leis, D.Lucas, Y.Mugnier, B.Nuber, J.Wachter|2001|Chem.-Eur.J.|7|1342|doi:10.1002/1521-3765(20010316)7:6<1342::AID-CHEM1342>3.0.CO;2-D

bis(mu~2~-1-Arsa-2-selenaethane)-bis(eta^5^-pentamethyl-cyclopentadienyl)-di-iron iodideSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 200715: Experimental Crystal Structure Determination

2003

Related Article: H.Brunner, M.M.Kubicki, A.Lange, J.Wachter, E.Vigier, M.Zabel|2003|Angew.Chem.,Int.Ed.|42|3547|doi:10.1002/anie.200350931

Space GroupCrystallography(mu~2~-Stibinosulfide-SSSbSb)-tetracarbonyl-bis(eta^5^-pentamethylcyclopentadienyl)-di-molybdenum hexafluorophosphate tetrahydrofuran solvateCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 127033: Experimental Crystal Structure Determination

2000

Related Article: H.Brunner, D.Lucas, T.Monzon, Y.Mugnier, B.Nuber, B.Stubenhofer, A.C.Stuckl, J.Wachter, R.Wanninger, M.Zabel|2000|Chem.-Eur.J.|6|493|doi:10.1002/(SICI)1521-3765(20000204)6:3<493::AID-CHEM493>3.0.CO;2-E

Space GroupCrystallography(mu~4~-Tellurido)-(mu~3~-tellurido)-bis(eta^5^-ethyltetramethylcyclopentadienyl)-heptacarbonyl-tri-cobalt-niobium(iii)Crystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 100092: Experimental Crystal Structure Determination

1997

Related Article: O.Blacque, H.Brunner, M.M.Kubicki, B.Nuber, B.Stubenhofer, J.Wachter, B.Wrackmeyer|1997|Angew.Chem.,Int.Ed.|36|352|doi:10.1002/anie.199703521

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters(mu~4~-Cyclotetratellurido)-icosacarbonyl-tetra-chromiumExperimental 3D Coordinates
researchProduct

CCDC 101348: Experimental Crystal Structure Determination

1999

Related Article: O.Blacque, H.Brunner, M.M.Kubicki, D.Lucas, W.Meier, Y.Mugnier, B.Nuber, B.Stubenhofer, J.Wachter|1998|J.Organomet.Chem.|564|71|doi:10.1016/S0022-328X(98)00615-9

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameterstetrakis(mu~2~-Selenido)-bis(decamethyl-niobocenyl(v))-molybdenum toluene solvateExperimental 3D Coordinates
researchProduct

CCDC 203183: Experimental Crystal Structure Determination

2003

Related Article: H.Brunner, H.Cattey, W.Meier, Y.Mugnier, A.C.Stuckl, J.Wachter, R.Wanninger, M.Zabel|2003|Chem.-Eur.J.|9|3796|doi:10.1002/chem.200304841

Space GroupCrystallographybis(mu~6~-tellurido)-pentakis(mu~4~-tellurido)-pentakis(dimethyl(phenyl)phosphine)-hexacarbonyl-undeca-cobalt toluene solvateCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 161795: Experimental Crystal Structure Determination

2002

Related Article: O.Blacque, H.Brunner, M.M.Kubicki, J.-C.Leblanc, W.Meier, C.Moise, Y.Mugnier, A.Sadorge, J.Wachter, M.Zabel|2001|J.Organomet.Chem.|634|47|doi:10.1016/S0022-328X(01)01085-3

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parametersbis(eta^5^-Pentamethyl-cyclopentadienyl)-(phenylthiocarbamato-S)-oxo-niobiumExperimental 3D Coordinates
researchProduct

CCDC 143349: Experimental Crystal Structure Determination

2001

Related Article: O.Blacque, H.Brunner, M.M.Kubicki, F.Leis, D.Lucas, Y.Mugnier, B.Nuber, J.Wachter|2001|Chem.-Eur.J.|7|1342|doi:10.1002/1521-3765(20010316)7:6<1342::AID-CHEM1342>3.0.CO;2-D

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters(mu~2~-eta^4^eta^4^-14-Diselena-23-diarsabuta-13-diene)-bis(eta^5^-pentamethyl-cyclopentadienyl)-di-ironExperimental 3D Coordinates
researchProduct

CCDC 161797: Experimental Crystal Structure Determination

2002

Related Article: O.Blacque, H.Brunner, M.M.Kubicki, J.-C.Leblanc, W.Meier, C.Moise, Y.Mugnier, A.Sadorge, J.Wachter, M.Zabel|2001|J.Organomet.Chem.|634|47|doi:10.1016/S0022-328X(01)01085-3

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parametersbis(eta^5^-Pentamethyl-cyclopentadienyl)-(phenylcarbamato-O)-oxo-niobiumExperimental 3D Coordinates
researchProduct

CCDC 182719: Experimental Crystal Structure Determination

2003

Related Article: M.Brandl, H.Brunner, H.Cattey, Y.Mugnier, J.Wachter, M.Zabel|2002|J.Organomet.Chem.|659|22|doi:10.1016/S0022-328X(02)01663-7

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parametersbis(mu~3~-Tellurido)-(mu~2~-bis(diphenylphosphino)methane)-heptacarbonyl-tri-ruthenium toluene solvateExperimental 3D Coordinates
researchProduct

CCDC 143350: Experimental Crystal Structure Determination

2001

Related Article: O.Blacque, H.Brunner, M.M.Kubicki, F.Leis, D.Lucas, Y.Mugnier, B.Nuber, J.Wachter|2001|Chem.-Eur.J.|7|1342|doi:10.1002/1521-3765(20010316)7:6<1342::AID-CHEM1342>3.0.CO;2-D

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parametersbis(mu~2~-1-Arsa-2-selenaethane)-bis(eta^5^-pentamethyl-cyclopentadienyl)-di-iron hexafluorophosphateExperimental 3D Coordinates
researchProduct

CCDC 127035: Experimental Crystal Structure Determination

2000

Related Article: H.Brunner, D.Lucas, T.Monzon, Y.Mugnier, B.Nuber, B.Stubenhofer, A.C.Stuckl, J.Wachter, R.Wanninger, M.Zabel|2000|Chem.-Eur.J.|6|493|doi:10.1002/(SICI)1521-3765(20000204)6:3<493::AID-CHEM493>3.0.CO;2-E

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parametersbis(Dicarbonyl-bis(eta^5^-pentamethylcyclopentadienyl)-niobium(iii)) (mu~8~-cobalt)-hexakis(mu~4~-tellurido)-octakis(carbonyl-cobalt)Experimental 3D Coordinates
researchProduct

CCDC 171079: Experimental Crystal Structure Determination

2003

Related Article: M.Brandl, H.Brunner, H.Cattey, Y.Mugnier, J.Wachter, M.Zabel|2002|J.Organomet.Chem.|659|22|doi:10.1016/S0022-328X(02)01663-7

Space GroupCrystallographyDicarbonyl-bis(eta^5^-pentamethyl-cyclopentadienyl)-niobium (mu~4~-tellurido)-tris(mu~2~-carbonyl)-tetracarbonyl-penta-rutheniumCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 127034: Experimental Crystal Structure Determination

2000

Related Article: H.Brunner, D.Lucas, T.Monzon, Y.Mugnier, B.Nuber, B.Stubenhofer, A.C.Stuckl, J.Wachter, R.Wanninger, M.Zabel|2000|Chem.-Eur.J.|6|493|doi:10.1002/(SICI)1521-3765(20000204)6:3<493::AID-CHEM493>3.0.CO;2-E

bis((eta^5^-Ethyltetramethylcyclopentadienyl)-carbonyl)-niobium(iii) tetracarbonyl-cobaltSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 117621: Experimental Crystal Structure Determination

1999

Related Article: O.Blacque, H.Brunner, M.M.Kubicki, D.Lucas, W.Meier, Y.Mugnier, B.Nuber, B.Stubenhofer, J.Wachter|1998|J.Organomet.Chem.|564|71|doi:10.1016/S0022-328X(98)00615-9

tetrakis(mu~2~-Sulfido)-bis(decamethyl-niobocenyl(v))-molybdenum toluene solvateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 101704: Experimental Crystal Structure Determination

1999

Related Article: H.Brunner, J.-C.Leblanc, D.Lucas, W.Meier, C.Moise, Y.Mugnier, B.Nuber, S.Rigny, A.Sadorge, J.Wachter|1998|J.Organomet.Chem.|566|203|doi:10.1016/S0022-328X(98)00746-3

Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersFluoro-hydroxy-bis(eta^5^-pentamethyl-cyclopentadienyl)-niobium tetrafluoroborateExperimental 3D Coordinates
researchProduct

CCDC 101705: Experimental Crystal Structure Determination

1999

Related Article: H.Brunner, J.-C.Leblanc, D.Lucas, W.Meier, C.Moise, Y.Mugnier, B.Nuber, S.Rigny, A.Sadorge, J.Wachter|1998|J.Organomet.Chem.|566|203|doi:10.1016/S0022-328X(98)00746-3

Space GroupCrystallographyCrystal SystemCrystal Structure(eta^5^-Pentamethyl-cyclopentadienyl)-formato-oxo-niobiumCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 161796: Experimental Crystal Structure Determination

2002

Related Article: O.Blacque, H.Brunner, M.M.Kubicki, J.-C.Leblanc, W.Meier, C.Moise, Y.Mugnier, A.Sadorge, J.Wachter, M.Zabel|2001|J.Organomet.Chem.|634|47|doi:10.1016/S0022-328X(01)01085-3

Space GroupCrystallographyCrystal Systembis(eta^5^-Pentamethyl-cyclopentadienyl)-hydrido-(phenylcarbamato-NO)-niobiumCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct